Skip to main content
. 2013 Jul;87(14):8075–8084. doi: 10.1128/JVI.00577-13

Fig 4.

Fig 4

The HBc L60V variation causes CTL-mediated liver injury in HBV transgenic mice. F1 hybrids of HLA-A2.1/Kb transgenic mice and HBV transgenic BALB/c mice were immunized three times, as described in the legend to Fig. 2. (A) Serum ALT activity was measured at 2-week intervals after the first immunization. (B) ELISPOT assay. Splenocytes from immunized mice were stimulated with L60 or V60 peptide or with HBc82-90 or HBc18-27 as negative and positive controls, respectively. (C) Cytotoxicity assay. HepG2 cells labeled with CFSE were transfected with pHBV1.3 or pHBV1.3-HBcL60V as target cells and mixed with L60, V60, HBc18-27, or HBc82-90 peptide-stimulated splenocytes at the indicated ratios. HBV transgenic BALB/c mice were immunized with the DNA prime/peptide boost formula as described in the text. (D) Serum ALT activity was measured every week. (E) Splenocytes from immunized mice were stimulated with the L60 or V60 peptide or with HBc82-90 or HBc87-95 as the negative and positive controls, respectively. The data show the means ± SDs of five mice. *, P < 0.05; **, P < 0.01.